Compare AMETEK, Inc. (AME) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Smith & Nephew plc — how do they compare? AMETEK, Inc. trades at $233.83 (market cap $53.63B), while Smith & Nephew plc trades at $31.14 (market cap $12.69B). The key difference: AMETEK, Inc. is far larger — about 4.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.55%). Which is the better fit depends on your goals.
| AME | SNN | |
|---|---|---|
Market Cap | $53.63B | $12.69B |
Sector | Industrials | Health |
52-Week High | $241.94 | $38.70 |
52-Week Low | $176.44 | $28.73 |
Enterprise Value | $55.33B | $15.46B |
Dividend Yield | 0.58% | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $233.98, up 0.42% today, with a neutral technical signal and strong fundamentals including three consecutive quarterly EPS beats. The company maintains robust profitability with a 20.11% net margin and recently completed the acquisition of First Aviation Services, expanding its aerospace and defense footprint. Cash flow remains positive with $83.95M net inflow in 2025.
Outlook is positive with a $260 consensus price target representing 11% upside, supported by 68.97% analyst buy ratings. Risks include elevated P/E of 35.34 and integration challenges from recent acquisitions. The stock offers growth exposure to industrial technology and aerospace sectors with stable dividend payments.
Smith & Nephew (SNN) trades at $30.70, up 0.99% with a bullish technical signal supported by moving averages. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B (2024-2025) and net income margin expanding to 10.14%. Recent developments include new medical guidance publications and robotics platform advancements, while analyst consensus remains cautious with 68% hold ratings.
SNN presents a mixed outlook with strong profitability metrics and positive cash flow trends offset by recent earnings misses and conservative analyst sentiment. Investment opportunity lies in the company's medical technology innovations and margin expansion, though risks include competitive pressures and execution challenges in meeting growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
